乐普医疗突破国际巨头垄断

Core Insights - Lepu Medical's rechargeable implantable deep brain stimulation (DBS) system has received approval from the National Medical Products Administration (NMPA), marking a significant breakthrough in China's neurostimulation field, traditionally dominated by international giants [2][4]. Product Approval - The approved DBS system consists of three components: a rechargeable implantable DBS device, an electrode component, and an extension lead kit, aimed at treating symptoms in advanced primary Parkinson's disease patients who do not respond effectively to medication [2]. - This approval is expected to contribute to Lepu Medical's revenue in the coming year, as indicated in their recent earnings presentation [2]. Market Potential - The global deep brain stimulation system market is projected to grow from approximately $1.738 billion in 2024 to $3.919 billion by 2031, with a compound annual growth rate (CAGR) of 12.5% from 2025 to 2031 [5]. - The rechargeable implantable DBS market is expected to generate around $690 million in revenue in 2024, reaching nearly $940 million by 2031, with a CAGR of 4.7% during the same period [5]. Competitive Landscape - The DBS market is currently dominated by major international players such as Boston Scientific, Medtronic, and Abbott, while domestic competitors like Lepu Medical and Beijing Pinchi Medical are emerging in the Chinese market [5]. - The rise of domestic neurostimulation devices is seen as a potential opportunity for import substitution, providing patients with more treatment options and enhancing competition in the high-tech medical device sector [6]. Industry Trends - The neuroprosthetics market is expected to grow at a CAGR of 13% from 2025 to 2031, driven by the increasing prevalence of neurological diseases due to global aging [6]. - Future advancements in neuroprosthetic devices are anticipated to leverage artificial intelligence and machine learning, improving functionality and precision in brain-computer interfaces [6].